Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
FDA Accepts Tanabe’s EPP/XLP Drug for Priority Review
Tanabe Pharma said on September 18 that the US FDA has accepted its application for dersimelagon, an oral selective melanocortin 1 receptor agonist being developed for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The application, which has been granted priority…
To read the full story
Related Article
- LEO Pharma Buys Global Rights to Tanabe’s EPP/XLP Drug
August 19, 2026
- Tanabe Unveils PIII Data for EPP/XLP Therapy, Backing Filing Plans
March 31, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
BUSINESS
- FDA Accepts Tanabe’s EPP/XLP Drug for Priority Review
September 24, 2026
- Moderna Launches XFG-Updated mNEXSPIKE in Japan
September 24, 2026
- Japan OKs FoundationOne CDx for Pfizer’s Lorbrena
September 24, 2026
- Takeda Commits US$22.2 Million to Climate-Resilient Health Systemss
September 24, 2026
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…